Midazolam Injectable Recalled for Silicone Particulate Matter Contamination
Exela Pharma Sciences is recalling Midazolam Injectable due to silicone particulate matter contamination. Patients and healthcare providers with the affected lot should discontinue use and consult their healthcare provider.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I classification requires a minimum severity score of 4. No deaths or serious injuries have been reported, but particulate matter in injectable medications represents a significant safety concern.
Plain-English summary
Exela Pharma Sciences, LLC is recalling Midazolam in 0.8% Sodium Chloride Injection due to the presence of silicone particulate matter. The product is a sedative medication administered intravenously and is distributed as 100 mL single-dose vials.
The recall affects Lot #10001088 with an expiration date of July 31, 2024. Approximately 23,425 vials were distributed nationwide to healthcare facilities.
Healthcare providers and facilities that received this product lot should stop using it immediately and identify any patients who received doses from the affected vials. Any adverse health effects potentially related to this product should be reported to the FDA.
Patients who received Midazolam from the affected lot should consult their healthcare provider for guidance regarding any health concerns.
The recalled product
- Product
- Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-
- Manufacturer
- Exela Pharma Sciences LLC
- Category
- Drug — Injectable / IV Drug
- Hazard
- silicone-particles
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot # 10001088 exp 07/31/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27